Lilly follows fellow drugmaker Johnson & Johnson, who sued the Health and Human Services Department on Tuesday, accusing the ...

A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...

Backed by the Economic Development Board (EDB), the hub was launched on Nov 14 at the Lilly Digital Health and Lilly Centre ...

The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

"We are delighted with Eli Lilly's decision to establish its Digital Health Innovation Hub in Singapore. This will strengthen ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.